Are you Dr. Ajani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 91 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Jaffer Ajani, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center and is a Professor of Medicine at University Tex Houston.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1982
Tulane UniversityResidency, Internal Medicine, 1977 - 1980
UPMC Medical Education/Altoona HospitalResidency, Family Medicine, 1975 - 1977- UPMC Medical Education/Altoona HospitalInternship, Transitional Year, 1974 - 1975
Indira Gandhi Medical CollegeClass of 1973
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 1980 - 2025
OK State Medical License 2020 - 2021
LA State Medical License 1977 - 1989- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
Clinical Trials
- SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed Start of enrollment: 1994 Mar 01
- Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Start of enrollment: 1998 Oct 01
- Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer Start of enrollment: 1999 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming.Gengyi Zou, Yuanjian Huang, Shengzhe Zhang, Kyung-Pil Ko, Bongjun Kim, Jie Zhang, Vishwa Venkatesan, Melissa P Pizzi, Yibo Fan, Sohee Jun, Na Niu, Huamin Wang, Shumei ...> ;The Journal of Experimental Medicine. 2024 Apr 1
- Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.Matthew R Strickland, Eric M Lander, Michael K Gibson, David H Ilson, Jaffer A Ajani, Samuel J Klempner> ;Journal of the National Comprehensive Cancer Network. 2024 Mar 19
- First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 ...Janjigian, Y., Ajani, J., Moehler, M., Shen, L., Garrido, M., Gallardo, C., Wyrwicz, L., Yamaguchi, K., Cleary, J., Elimova, E., Karamouzis, M., Bruges, R., Skoczylas,...> ;Journal of Clinical Oncology. 2024 Feb 21
- Join now to see all
Press Mentions
New Insights into Biology, Origin of Deadly Stomach and Esophageal CancersOctober 27th, 2022- Immunotherapy Is Now the First Choice for Esophageal CancerMay 31st, 2022
- BMS’ Opdivo Gets Late-Stage Oesophageal Cancer Nod from FDAMay 29th, 2022
- Join now to see all
Grant Support
- Prediction Of Pathologic Complete Response By Gene Expression Profiling In EsophaNational Cancer Institute2010–2012
- Molecular Biomarkers As Classifiers To Individualize Therapy Of Esophagus CancerNational Cancer Institute2009–2010
- Molecular Markers Of Response To Chemoradiation In Localized Esophageal CancerNational Cancer Institute2008–2009
Professional Memberships
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
